Compugen (CGEN) Competitors $1.53 -0.01 (-0.65%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.56 +0.02 (+1.63%) As of 07/25/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. ORKA, ARVN, RAPP, ATYR, OPT, PGEN, SLDB, TERN, TRML, and PRTCShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Oruka Therapeutics (ORKA), Arvinas (ARVN), Rapport Therapeutics (RAPP), aTyr Pharma (ATYR), Opthea (OPT), Precigen (PGEN), Solid Biosciences (SLDB), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Its Competitors Oruka Therapeutics Arvinas Rapport Therapeutics aTyr Pharma Opthea Precigen Solid Biosciences Terns Pharmaceuticals Tourmaline Bio PureTech Health Compugen (NASDAQ:CGEN) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Which has higher valuation & earnings, CGEN or ORKA? Compugen has higher revenue and earnings than Oruka Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.59M4.95-$14.23M-$0.16-9.56Oruka TherapeuticsN/AN/A-$83.72M-$4.51-3.16 Which has more volatility and risk, CGEN or ORKA? Compugen has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500. Do analysts recommend CGEN or ORKA? Compugen presently has a consensus target price of $4.00, indicating a potential upside of 161.44%. Oruka Therapeutics has a consensus target price of $40.38, indicating a potential upside of 183.33%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Is CGEN or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to Compugen's net margin of -51.27%. Compugen's return on equity of -24.51% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compugen-51.27% -24.51% -12.19% Oruka Therapeutics N/A -25.66%-23.39% Do institutionals & insiders hold more shares of CGEN or ORKA? 12.2% of Compugen shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer CGEN or ORKA? In the previous week, Oruka Therapeutics had 7 more articles in the media than Compugen. MarketBeat recorded 10 mentions for Oruka Therapeutics and 3 mentions for Compugen. Compugen's average media sentiment score of 0.63 beat Oruka Therapeutics' score of 0.45 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOruka Therapeutics beats Compugen on 9 of the 16 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$137.43M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-9.5621.1828.1020.05Price / Sales4.95288.62432.4890.19Price / CashN/A42.7636.2258.56Price / Book2.478.378.665.87Net Income-$14.23M-$55.19M$3.25B$258.55M7 Day Performance-0.65%5.88%4.22%3.73%1 Month Performance-6.13%17.33%10.51%11.75%1 Year Performance-13.56%4.42%34.40%18.03% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen1.4458 of 5 stars$1.53-0.6%$4.00+161.4%-13.1%$137.43M$27.59M-9.5670ORKAOruka Therapeutics2.7217 of 5 stars$13.77-5.3%$40.38+193.2%N/A$544.39MN/A-3.05N/AUpcoming EarningsAnalyst ForecastARVNArvinas4.031 of 5 stars$7.52+2.3%$20.29+169.8%-73.4%$536.49M$263.40M-11.39420News CoverageUpcoming EarningsRAPPRapport Therapeutics1.5043 of 5 stars$14.39-2.0%$28.00+94.6%-27.7%$535.79MN/A-4.17N/ANews CoverageATYRaTyr Pharma2.1761 of 5 stars$5.71-4.7%$20.20+253.8%+161.4%$533.14M$230K-7.0553News CoverageGap UpHigh Trading VolumeOPTOpthea0.3847 of 5 stars$3.41+7.2%$1.33-60.9%+55.0%$524.84M$120K0.008News CoverageGap UpPGENPrecigen3.8544 of 5 stars$1.83+4.0%$6.00+227.9%-5.4%$519.52M$3.92M-3.27190Positive NewsSLDBSolid Biosciences3.0988 of 5 stars$6.37-0.3%$15.10+137.0%-22.7%$495.32M$8.09M-2.13100High Trading VolumeTERNTerns Pharmaceuticals3.9798 of 5 stars$5.64flat$15.63+177.0%-31.2%$492.58MN/A-5.1740TRMLTourmaline Bio1.7459 of 5 stars$18.23-1.4%$49.33+170.6%+15.5%$474.67MN/A-5.6844News CoveragePRTCPureTech Health2.7886 of 5 stars$18.56+0.3%$45.00+142.4%-14.4%$472.52M$4.83M0.00100Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Oruka Therapeutics Alternatives Arvinas Alternatives Rapport Therapeutics Alternatives aTyr Pharma Alternatives Opthea Alternatives Precigen Alternatives Solid Biosciences Alternatives Terns Pharmaceuticals Alternatives Tourmaline Bio Alternatives PureTech Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEN Stock Alerts